94 results
Page 2 of 5
8-K
EX-99.1
2xy jzbhv1ry
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
PRE 14A
50ae1ar1a1roks n0e4r
17 Apr 23
Preliminary proxy
5:04pm
8-K
EX-99.1
81f5rf59172b zl2fatn
3 Apr 23
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares
5:17pm
8-K
03y rm0k90w5hg5nds50
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
8-K
EX-99.1
yb3i9my2gqz1
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
424B5
2ovghmgwta80
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
jki69i8ea4g
29 Mar 23
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
pl2cj y2bolazmt
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
j7t482v4w2
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
mq1a5t 66t
27 Apr 22
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
nrcnxs
9 Feb 22
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
h3cu c3w0pv3
3 Nov 21
Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
424B5
8oqv6wy gtjj
11 Aug 21
Prospectus supplement for primary offering
4:44pm
8-K
emqxxamj8b6w
28 Jul 21
Entry into a Material Definitive Agreement
5:14pm